USNA USANA: שווי פעילות לרווח לפני ריבית, מסים ופחת

Asian regulatory risks and raw material inflation are weighing on USANA Health Sciences (USNA) revenue. The EV/EBITDA multiple, accounting for financial leverage, confirms a gap between price and intrinsic value, with this metric equal to 1.40. Targeted updates to R&D formulas and applications complement a direct-sales business model for dietary supplements, which relies on customer loyalty in the Asia-Pacific region and the global wellness market.

This multiple determines the business value relative to its operating profit before depreciation and taxes, allowing for an assessment of the real value of assets regardless of the debt load. Analyzing the EV/EBITDA ratio of a heavy business helps investors identify the fundamental undervaluation of USANA Health Sciences (USNA) during a period of product portfolio stagnation and targeted updates to the nutraceutical R&D cycle.